Consensus Regarding Multiple-Day and Rescue Antiemetic Therapy

  • Pieter H. M. De Mulder
  • Fausto Roila
  • Mark G. Kris
  • Michel M. Marty
Conference paper


Different forms of moderately and highly emetogenic cancer chemotherapy that are administered over several days per cycle are discussed with reference to the most efficacious antiemetic therapy. Both preventive and rescue antiemetic therapy are considered.


Complete Protection Emetogenic Chemotherapy Antiemetic Therapy Extrapyramidal Side Effect Oral Cyclophosphamide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Basurto C, Rolla F, Tonato M et al (1989) Antiemetic activity of high-dose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients. Am J Clin Oncol 12: 235–238PubMedCrossRefGoogle Scholar
  2. 2.
    Bremer K on behalf of the granisetron study group (1992) A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy. Eur J Cancer [A] 28: 1018–1022CrossRefGoogle Scholar
  3. 3.
    Buser KS, Joss RA, Piquet D et al (1993) Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind placebocontrolled study. Ann Oncol 4: 474–479Google Scholar
  4. 4.
    deBoer M, de Wit R, Stoter G, Verweij J (1995) Possible lack of full cross-resistance of 5HT3 antagonists: a pilot study. Cancer Res Clin Oncol 121: 126–127Google Scholar
  5. 5.
    Depierre A, Lebeau B, Chevallier B et al (1996) Efficay of ondansetron, methylprednisolone plus metopimazine in patients previously incontrolled with dual therapy in cisplatin containing chemotherapy (abstract). Ann Oncol 7: 134Google Scholar
  6. 6.
    Domínguez-Ortega L, Cubedo-Cervera R, Cortés-Funés H, Díaz-Gallego E (1996) Sleep protects against chemotherapy induces emesis. Cancer 77: 1566–1570PubMedCrossRefGoogle Scholar
  7. 7.
    Falkson C, Falkson H (1995) Antiemetic efficacy of tropisetron in patients failing previous antiemetic therapy. Oncology 52: 427–431PubMedCrossRefGoogle Scholar
  8. 8.
    Fox SM, Einhorn LH, Cox E et al (1993) Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11: 2391–2395PubMedGoogle Scholar
  9. 9.
    Einhorn LH, Naggy C, Werner K et al (1990) Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 8: 731–735PubMedGoogle Scholar
  10. 10.
    Hainsworth JD (1992) The use of ondansetron in patients receiving multiple-day cisplatin regimens. Semin Oncol 19: 48–52PubMedGoogle Scholar
  11. 11.
    Herman TS, Einhorn LH, Jones SE et al (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300: 1295–1297PubMedCrossRefGoogle Scholar
  12. 12.
    Italian Group for Antiemetic Research (1992) Ondansetron + dexamethasone versus metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin induced emesis. Lancet 340: 96–99CrossRefGoogle Scholar
  13. 13.
    Levitt M, Warr D,Yelle L et al (1993) Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate and fluorouracil. N Engl J Med 328: 1081–1084PubMedCrossRefGoogle Scholar
  14. 14.
    Mantovani G, Macciò A, Alessandro B, Curelli L, Ghiani M, Proto E (1996) Comparison of granisetron versus ondansetron versus tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 77: 941–948PubMedCrossRefGoogle Scholar
  15. 15.
    Nicolai N, Mangiarotti B, Salvioni R et al (1993) Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induce by cisplatincontaining chemotherapies for urological cancers. Eur Urol 23: 450–456PubMedGoogle Scholar
  16. 16.
    Rath U, Upadhyaya BK, Arechavala E, et al (1993) Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 50: 168–172PubMedCrossRefGoogle Scholar
  17. 17.
    Sledge GW, Einhorn LH, Nagy C et al (1992) Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 70: 2524–2528PubMedCrossRefGoogle Scholar
  18. 18.
    Tyson LB, Clark RA, Gralla RJ (1982) High dose metoclopramide: control of dacarbazine-induced emesis in a preliminary trial. Cancer Treat Rep 66: 2108PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Pieter H. M. De Mulder
  • Fausto Roila
  • Mark G. Kris
  • Michel M. Marty

There are no affiliations available

Personalised recommendations